New drug shows promise for bipolar depression in early trial
NCT ID NCT06869187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug called ABX-002 to current treatments can improve depression symptoms in adults with bipolar disorder. About 30 people with bipolar depression will take the drug for 6 weeks, and some will have brain scans to see how it affects brain chemistry. The goal is to find a better way to ease depressive episodes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Autobahn Site #201
Cromwell, Connecticut, 06416, United States
-
Autobahn Site #203
Brooklyn, New York, 11235, United States
-
Autobahn Site #204
Staten Island, New York, 10314, United States
-
Autobahn Site #205
Marlton, New Jersey, 08053, United States
-
Autobahn Site #207
New York, New York, 10016, United States
-
Autobahn Site #208
Cherry Hill, New Jersey, 08002, United States
-
Autobahn Site #209
Hamilton, New Jersey, 08690, United States
-
Autobahn Site #210
Hartford, Connecticut, 06106, United States
-
Autobahn Site #211
New York, New York, 10019, United States
-
Autobahn Site #212
Miami, Florida, 33014, United States
-
Autobahn Site #213
Walnut Creek, California, 94596, United States
-
Autobahn Site #214
Bellevue, Washington, 98007, United States
-
Autobahn Site #215
Chicago, Illinois, 60622, United States
-
Autobahn Site #216
Worcester, Massachusetts, 01608, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.